Not known Facts About Imipenem
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate many intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Principal demo objectives ended up to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyo